GSK has just announced first quarter sales and they actually mentioned Relenza in a paragraph, although they said revenue was down 25% from the same quarter last year due to Japan not repeating stockpiling in 2015.
The GSK Relenza revenue was £30m or approx $US46m.
Unfortunately it is listed amongst "Other" in their table of sales, so we cannot track its sales in different regions...
...speaking of which, I recall Relenza Patents in Europe run out this month - can anyone confirm?
Anyway, 7% of 46m = a whopping $3.2m royalties from GSK for that quarter.
DS results should be due soon. Their last quarter Inavir sales (not sure whether they were reported here) were up 6% YoY, so will be interesting to see what the latest quarter figures are.
Anything to stem a little cash burn at this stage...while we wait for JP to pull a rabbit out of his hat.
Ahoy Joseph - what's been happening?
- Forums
- ASX - By Stock
- BTA
- Royalties
Royalties
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BPH
BPH ENERGY LTD
David Breeze, Managing Director and Executive Chairman
David Breeze
Managing Director and Executive Chairman
SPONSORED BY The Market Online